ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2540

Impact of IL34, IFN-α and IFN-λ1 on Disease Activity of SLE Patients in Egypt

Yasmin Hussein1 and Yousra Sadeq 1, 1Mansoura University Hospital, Mansoura, Egypt

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: IL and INF, SLE

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 12, 2019

Title: SLE – Clinical Poster III: Treatment

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: SLE is a systemic inflammatory and autoimmune disease. IL-34 plays pivotal roles in the proliferation and differentiation of mononuclear phagocyte cells, osteoclastogenesis and inflammation. IFN-α play an important role in SLE pathogenesis and proportion of patients displays increased serum IFN-α and IFN-λ1. Interestingly, the gene signatures of IFN-λ1 and IFN-α overlap. Our objective was to assess IL34, IFN-λ1 and IFN-α in SLE with relationship to clinical, laboratory parameters, treatment response and disease progression. We hypothesized a subgroup of patient with a concordance of high level of these cytokines that could have a different disease behavior.

Methods: 82 newly diagnosed SLE Egyptian patients. History, examination and laboratory investigation with assessment of disease activity. Pretreatment assessment of IL34, IFN-α and IFN-λ1 level by ILIZA. Patients started treatment (antimalarial ±Steroid ±immunosuppressive drugs) with response evaluation after six months.

Results: 14 male (17.1%) and 68 female (82.9%), age mean±SD (48.6±8.2).  Mean±SD of IL34, INFα and INF-λ1were 175.9±125.9 pg/mL, 109.3±32.5 pg/mL and 227.9±144.8 pg/mL respectively. 21 patients (25.6%) had lupus nephritis, 32 patients (39%) with SLAM >6 and 22 patients (26.8%) with SLEDAI >6. IL34 was positively correlated with anti-dsDNA (P= 0.002) but inversely correlated with C3 level (P = 0.009). IL34 was highly presented with lupus nephritis (P 0.005), SLAM >6 (P 0.03), SLEDAI >6 (P 0.007) and poor responder to treatment (P 0.02). IFNα was inversely correlated with C3 (P 0.001). IFNα was highly presented with lupus nephritis (P 0.02) and poor responders (P 0.01) however no relation with SLAM >6 nor SLEDAI >6. INF-λ1 was positively correlated with anti-dsDNA (P= 0.02) but inversely correlated with C3 (P = 0.01). INF-λ1 was highly presented with lupus nephritis (P 0.001), with SLAM >6 (P 0.04), with SLEDAI >6 (P 0.02). Accumulation of ≥3 clinical features during follow up was associated with high IL34 (P 0.001), high IFNα (P 0.001) and high INF-λ1 (P 0.001). We assigned high levels (i.e., ≥ 75% or third quartile) of each cytokine. Triple high (IL34high, IFNα high and IFN-λ1 high)  found in 17 patients (20.7%) and were positively correlated with anti-dsDNA (P= 0.001) but inversely correlated with C3 (P = 0.001). Triple cytokines level was highly presented with lupus nephritis (P 0.001), SLAM >6 (P 0.02), SLEDAI >6 (P 0.03) and poor response to treatment (P 0.01) indicating these patients have aggressive disease. 28 patients developed (3 – 8) accumulated clinical features during the disease course, out of them 15 patients (53.5%) have high level of the triple cytokines indicating a poor prognosis of these subgroup.

Conclusion: High pretreatment serum IL-34 or IFN-λ1 has a prognostic significance in SLE patients. Patients with high IL-34 or IFNα or IFN-λ1 had more kidney affection and poor response to treatment. Triple cytokines elevation significantly associated with lupus disease activity, more kidney affection and poor response to treatment so, this aggressive phenotype of patients may be in need for combination of targets or a multicytokines targeted therapy.  


ACR


Disclosure: Y. Hussein, None; Y. Sadeq, None.

To cite this abstract in AMA style:

Hussein Y, Sadeq Y. Impact of IL34, IFN-α and IFN-λ1 on Disease Activity of SLE Patients in Egypt [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/impact-of-il34-ifn-%ce%b1-and-ifn-%ce%bb1-on-disease-activity-of-sle-patients-in-egypt/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/impact-of-il34-ifn-%ce%b1-and-ifn-%ce%bb1-on-disease-activity-of-sle-patients-in-egypt/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology